ID   SYFM_HUMAN              Reviewed;         451 AA.
AC   O95363; B2R664; Q53F66; Q5TCS3; Q6FG29; Q9NPY7; Q9P062;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   15-MAR-2017, entry version 155.
DE   RecName: Full=Phenylalanine--tRNA ligase, mitochondrial;
DE            EC=6.1.1.20 {ECO:0000269|PubMed:19549855, ECO:0000269|PubMed:22833457};
DE   AltName: Full=Phenylalanyl-tRNA synthetase;
DE            Short=PheRS;
DE   Flags: Precursor;
GN   Name=FARS2; Synonyms=FARS1; ORFNames=HSPC320;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBUNIT.
RX   PubMed=10329163; DOI=10.1006/jmbi.1999.2708;
RA   Bullard J.M., Cai Y.-C., Demeler B., Spremulli L.L.;
RT   "Expression and characterization of a human mitochondrial
RT   phenylalanyl-tRNA synthetase.";
RL   J. Mol. Biol. 288:567-577(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-280.
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-280.
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney epithelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 108-451, AND VARIANT
RP   SER-280.
RC   TISSUE=Umbilical cord blood;
RA   Ye M., Zhang Q.-H., Zhou J., Shen Y., Wu X.-Y., Guan Z.Q., Wang L.,
RA   Fan H.-Y., Mao Y.-F., Dai M., Huang Q.-H., Chen S.-J., Chen Z.;
RT   "Human partial CDS from CD34+ stem cells.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-202, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 38-451 IN COMPLEX WITH
RP   SUBSTRATE, AND SUBUNIT.
RX   PubMed=18611382; DOI=10.1016/j.str.2008.03.020;
RA   Klipcan L., Levin I., Kessler N., Moor N., Finarov I., Safro M.;
RT   "The tRNA-induced conformational activation of human mitochondrial
RT   phenylalanyl-tRNA synthetase.";
RL   Structure 16:1095-1104(2008).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 38-451 IN COMPLEX WITH
RP   SUBSTRATE, FUNCTION, CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND
RP   KINETIC PARAMETERS.
RX   PubMed=19549855; DOI=10.1073/pnas.0905212106;
RA   Klipcan L., Moor N., Kessler N., Safro M.G.;
RT   "Eukaryotic cytosolic and mitochondrial phenylalanyl-tRNA synthetases
RT   catalyze the charging of tRNA with the meta-tyrosine.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11045-11048(2009).
RN   [12]
RP   VARIANTS COXPD14 THR-329 AND VAL-391, CHARACTERIZATION OF VARIANTS
RP   COXPD14 CYS-144; THR-329 AND VAL-391, FUNCTION, CATALYTIC ACTIVITY,
RP   AND KINETIC PARAMETERS.
RX   PubMed=22833457; DOI=10.1093/hmg/dds294;
RA   Elo J.M., Yadavalli S.S., Euro L., Isohanni P., Gotz A., Carroll C.J.,
RA   Valanne L., Alkuraya F.S., Uusimaa J., Paetau A., Caruso E.M.,
RA   Pihko H., Ibba M., Tyynismaa H., Suomalainen A.;
RT   "Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal
RT   infantile Alpers encephalopathy.";
RL   Hum. Mol. Genet. 21:4521-4529(2012).
RN   [13]
RP   VARIANT COXPD14 CYS-144.
RX   PubMed=22499341; DOI=10.1136/jmedgenet-2012-100836;
RA   Shamseldin H.E., Alshammari M., Al-Sheddi T., Salih M.A.,
RA   Alkhalidi H., Kentab A., Repetto G.M., Hashem M., Alkuraya F.S.;
RT   "Genomic analysis of mitochondrial diseases in a consanguineous
RT   population reveals novel candidate disease genes.";
RL   J. Med. Genet. 49:234-241(2012).
RN   [14]
RP   VARIANT SPG77 TYR-142, AND CHARACTERIZATION OF VARIANT SPG77 TYR-142.
RX   PubMed=26553276; DOI=10.1002/humu.22930;
RA   Yang Y., Liu W., Fang Z., Shi J., Che F., He C., Yao L., Wang E.,
RA   Wu Y.;
RT   "A newly identified missense mutation in FARS2 causes autosomal-
RT   recessive spastic paraplegia.";
RL   Hum. Mutat. 37:165-169(2016).
CC   -!- FUNCTION: Is responsible for the charging of tRNA(Phe) with
CC       phenylalanine in mitochondrial translation. To a lesser extent,
CC       also catalyzes direct attachment of m-Tyr (an oxidized version of
CC       Phe) to tRNA(Phe), thereby opening the way for delivery of the
CC       misacylated tRNA to the ribosome and incorporation of ROS-damaged
CC       amino acid into proteins. {ECO:0000269|PubMed:19549855,
CC       ECO:0000269|PubMed:22833457}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-phenylalanine + tRNA(Phe) = AMP +
CC       diphosphate + L-phenylalanyl-tRNA(Phe).
CC       {ECO:0000269|PubMed:19549855, ECO:0000269|PubMed:22833457}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.2 uM for L-phenylalanine {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         KM=1900 uM for L-tyrosine {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         KM=11.7 uM for DL-m-tyrosine {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         KM=7.3 uM for L-phenylalanine {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         KM=2.9 mM for ATP {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         KM=1.2 uM for tRNA(Phe) {ECO:0000269|PubMed:19549855,
CC         ECO:0000269|PubMed:22833457};
CC         Note=kcat is 2.8 min(-1), 2.0 min(-1) and 3.1 min(-1) with L-
CC         phenylalanine, L-tyrosine and m-tyrosine as substrate,
CC         respectively. Thus, the catalytic efficiency of the m-Tyr
CC         attachment is only 5-fold lower than that of the correct amino
CC         acid, while that of Tyr attachment is 1000-fold lower
CC         (PubMed:19549855). {ECO:0000269|PubMed:19549855};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:10329163,
CC       ECO:0000269|PubMed:18611382, ECO:0000269|PubMed:19549855}.
CC   -!- INTERACTION:
CC       Q6UY14-3:ADAMTSL4; NbExp=3; IntAct=EBI-2513774, EBI-10173507;
CC       Q6RW13:AGTRAP; NbExp=3; IntAct=EBI-2513774, EBI-741181;
CC       Q9UKG1:APPL1; NbExp=5; IntAct=EBI-2513774, EBI-741243;
CC       Q13137:CALCOCO2; NbExp=5; IntAct=EBI-2513774, EBI-739580;
CC       Q96DZ9:CMTM5; NbExp=3; IntAct=EBI-2513774, EBI-2548702;
CC       Q6NT76:HMBOX1; NbExp=3; IntAct=EBI-2513774, EBI-2549423;
CC       Q9UKT9:IKZF3; NbExp=5; IntAct=EBI-2513774, EBI-747204;
CC       A1A4E9:KRT13; NbExp=3; IntAct=EBI-2513774, EBI-10171552;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-2513774, EBI-948001;
CC       Q6A162:KRT40; NbExp=5; IntAct=EBI-2513774, EBI-10171697;
CC       P60370:KRTAP10-5; NbExp=3; IntAct=EBI-2513774, EBI-10172150;
CC       P60409:KRTAP10-7; NbExp=3; IntAct=EBI-2513774, EBI-10172290;
CC       P60411:KRTAP10-9; NbExp=5; IntAct=EBI-2513774, EBI-10172052;
CC       Q9UJV3-2:MID2; NbExp=5; IntAct=EBI-2513774, EBI-10172526;
CC       Q13064:MKRN3; NbExp=3; IntAct=EBI-2513774, EBI-2340269;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-2513774, EBI-945833;
CC       O95199:RCBTB2; NbExp=5; IntAct=EBI-2513774, EBI-742404;
CC       O75558:STX11; NbExp=3; IntAct=EBI-2513774, EBI-714135;
CC       O75478:TADA2A; NbExp=3; IntAct=EBI-2513774, EBI-742268;
CC       Q12800:TFCP2; NbExp=3; IntAct=EBI-2513774, EBI-717422;
CC       P14373:TRIM27; NbExp=3; IntAct=EBI-2513774, EBI-719493;
CC       Q9BYV2:TRIM54; NbExp=3; IntAct=EBI-2513774, EBI-2130429;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000250|UniProtKB:Q6AYQ3}. Mitochondrion
CC       {ECO:0000250|UniProtKB:Q6AYQ3}.
CC   -!- DISEASE: Combined oxidative phosphorylation deficiency 14
CC       (COXPD14) [MIM:614946]: A severe multisystemic autosomal recessive
CC       disorder characterized by neonatal onset of global developmental
CC       delay, refractory seizures, and lactic acidosis. Biochemical
CC       studies show deficiencies of multiple mitochondrial respiratory
CC       enzymes. {ECO:0000269|PubMed:22499341,
CC       ECO:0000269|PubMed:22833457}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spastic paraplegia 77, autosomal recessive (SPG77)
CC       [MIM:617046]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. {ECO:0000269|PubMed:26553276}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF28998.1; Type=Frameshift; Positions=414; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF097441; AAC83802.1; -; mRNA.
DR   EMBL; AK312454; BAG35361.1; -; mRNA.
DR   EMBL; CR542279; CAG47075.1; -; mRNA.
DR   EMBL; AK223423; BAD97143.1; -; mRNA.
DR   EMBL; AL133473; CAI19901.1; -; Genomic_DNA.
DR   EMBL; AL022097; CAI19901.1; JOINED; Genomic_DNA.
DR   EMBL; AL590868; CAI19901.1; JOINED; Genomic_DNA.
DR   EMBL; AL121978; CAI19901.1; JOINED; Genomic_DNA.
DR   EMBL; AL392184; CAI19901.1; JOINED; Genomic_DNA.
DR   EMBL; AL022097; CAI19950.1; -; Genomic_DNA.
DR   EMBL; AL121978; CAI19950.1; JOINED; Genomic_DNA.
DR   EMBL; AL392184; CAI19950.1; JOINED; Genomic_DNA.
DR   EMBL; AL590868; CAI19950.1; JOINED; Genomic_DNA.
DR   EMBL; AL133473; CAI19950.1; JOINED; Genomic_DNA.
DR   EMBL; AL392184; CAI20375.1; -; Genomic_DNA.
DR   EMBL; AL121978; CAI20375.1; JOINED; Genomic_DNA.
DR   EMBL; AL590868; CAI20375.1; JOINED; Genomic_DNA.
DR   EMBL; AL133473; CAI20375.1; JOINED; Genomic_DNA.
DR   EMBL; AL022097; CAI20375.1; JOINED; Genomic_DNA.
DR   EMBL; AL121978; CAI21657.1; -; Genomic_DNA.
DR   EMBL; AL133473; CAI21657.1; JOINED; Genomic_DNA.
DR   EMBL; AL022097; CAI21657.1; JOINED; Genomic_DNA.
DR   EMBL; AL392184; CAI21657.1; JOINED; Genomic_DNA.
DR   EMBL; AL590868; CAI21657.1; JOINED; Genomic_DNA.
DR   EMBL; AL590868; CAI39442.1; -; Genomic_DNA.
DR   EMBL; AL392184; CAI39442.1; JOINED; Genomic_DNA.
DR   EMBL; AL133473; CAI39442.1; JOINED; Genomic_DNA.
DR   EMBL; AL121978; CAI39442.1; JOINED; Genomic_DNA.
DR   EMBL; AL022097; CAI39442.1; JOINED; Genomic_DNA.
DR   EMBL; BC020239; AAH20239.1; -; mRNA.
DR   EMBL; BC021112; AAH21112.1; -; mRNA.
DR   EMBL; AF161438; AAF28998.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS4494.1; -.
DR   RefSeq; NP_001305801.1; NM_001318872.1.
DR   RefSeq; NP_006558.1; NM_006567.4.
DR   RefSeq; XP_005248869.1; XM_005248812.3.
DR   RefSeq; XP_016865675.1; XM_017010186.1.
DR   RefSeq; XP_016865676.1; XM_017010187.1.
DR   UniGene; Hs.484547; -.
DR   PDB; 3CMQ; X-ray; 2.20 A; A=38-451.
DR   PDB; 3HFV; X-ray; 2.60 A; A=38-451.
DR   PDB; 3TEG; X-ray; 2.20 A; A=38-451.
DR   PDB; 3TUP; X-ray; 3.05 A; A=38-451.
DR   PDBsum; 3CMQ; -.
DR   PDBsum; 3HFV; -.
DR   PDBsum; 3TEG; -.
DR   PDBsum; 3TUP; -.
DR   ProteinModelPortal; O95363; -.
DR   SMR; O95363; -.
DR   BioGrid; 115909; 44.
DR   IntAct; O95363; 67.
DR   MINT; MINT-3077661; -.
DR   STRING; 9606.ENSP00000274680; -.
DR   BindingDB; O95363; -.
DR   ChEMBL; CHEMBL2511; -.
DR   DrugBank; DB00120; L-Phenylalanine.
DR   iPTMnet; O95363; -.
DR   PhosphoSitePlus; O95363; -.
DR   BioMuta; FARS2; -.
DR   EPD; O95363; -.
DR   MaxQB; O95363; -.
DR   PaxDb; O95363; -.
DR   PeptideAtlas; O95363; -.
DR   PRIDE; O95363; -.
DR   DNASU; 10667; -.
DR   Ensembl; ENST00000274680; ENSP00000274680; ENSG00000145982.
DR   Ensembl; ENST00000324331; ENSP00000316335; ENSG00000145982.
DR   GeneID; 10667; -.
DR   KEGG; hsa:10667; -.
DR   UCSC; uc003mwr.3; human.
DR   CTD; 10667; -.
DR   DisGeNET; 10667; -.
DR   GeneCards; FARS2; -.
DR   HGNC; HGNC:21062; FARS2.
DR   HPA; HPA018148; -.
DR   HPA; HPA028836; -.
DR   MalaCards; FARS2; -.
DR   MIM; 611592; gene.
DR   MIM; 614946; phenotype.
DR   MIM; 617046; phenotype.
DR   neXtProt; NX_O95363; -.
DR   OpenTargets; ENSG00000145982; -.
DR   Orphanet; 319519; Combined oxidative phosphorylation defect type 14.
DR   PharmGKB; PA134954893; -.
DR   eggNOG; KOG2783; Eukaryota.
DR   eggNOG; COG0016; LUCA.
DR   eggNOG; COG0072; LUCA.
DR   GeneTree; ENSGT00530000063467; -.
DR   HOGENOM; HOG000165163; -.
DR   HOVERGEN; HBG082540; -.
DR   InParanoid; O95363; -.
DR   KO; K01889; -.
DR   OMA; TYFPFTQ; -.
DR   OrthoDB; EOG091G07OD; -.
DR   PhylomeDB; O95363; -.
DR   TreeFam; TF105798; -.
DR   BRENDA; 6.1.1.20; 2681.
DR   Reactome; R-HSA-379726; Mitochondrial tRNA aminoacylation.
DR   ChiTaRS; FARS2; human.
DR   EvolutionaryTrace; O95363; -.
DR   GeneWiki; FARS2; -.
DR   GenomeRNAi; 10667; -.
DR   PRO; PR:O95363; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000145982; -.
DR   CleanEx; HS_FARS2; -.
DR   ExpressionAtlas; O95363; baseline and differential.
DR   Genevisible; O95363; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004826; F:phenylalanine-tRNA ligase activity; IDA:UniProtKB.
DR   GO; GO:0000049; F:tRNA binding; IDA:UniProtKB.
DR   GO; GO:0006432; P:phenylalanyl-tRNA aminoacylation; IDA:UniProtKB.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   GO; GO:0008033; P:tRNA processing; IDA:UniProtKB.
DR   Gene3D; 3.30.70.380; -; 1.
DR   InterPro; IPR006195; aa-tRNA-synth_II.
DR   InterPro; IPR005121; Fdx_antiC-bd.
DR   InterPro; IPR004530; Phe-tRNA-synth_IIc_mito.
DR   InterPro; IPR002319; Phenylalanyl-tRNA_Synthase.
DR   PANTHER; PTHR11538:SF53; PTHR11538:SF53; 1.
DR   Pfam; PF03147; FDX-ACB; 1.
DR   Pfam; PF01409; tRNA-synt_2d; 2.
DR   SMART; SM00896; FDX-ACB; 1.
DR   SUPFAM; SSF54991; SSF54991; 1.
DR   TIGRFAMs; TIGR00469; pheS_mito; 1.
DR   PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
DR   PROSITE; PS51447; FDX_ACB; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminoacyl-tRNA synthetase; ATP-binding;
KW   Complete proteome; Disease mutation; Hereditary spastic paraplegia;
KW   Ligase; Mitochondrion; Neurodegeneration; Nucleotide-binding;
KW   Polymorphism; Protein biosynthesis; Reference proteome;
KW   Transit peptide.
FT   TRANSIT       1      ?       Mitochondrion. {ECO:0000255}.
FT   CHAIN         ?    451       Phenylalanine--tRNA ligase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000035813.
FT   DOMAIN      358    450       FDX-ACB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00778}.
FT   REGION      157    160       Substrate binding.
FT   REGION      186    188       Substrate binding.
FT   REGION      193    195       Substrate binding.
FT   BINDING     179    179       Substrate. {ECO:0000269|PubMed:18611382,
FT                                ECO:0000269|PubMed:19549855}.
FT   BINDING     287    287       Substrate; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:18611382,
FT                                ECO:0000269|PubMed:19549855}.
FT   BINDING     312    312       Substrate; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:18611382,
FT                                ECO:0000269|PubMed:19549855}.
FT   MOD_RES     202    202       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VARIANT      57     57       S -> C (in dbSNP:rs34382405).
FT                                /FTId=VAR_052642.
FT   VARIANT     142    142       D -> Y (in SPG77; resulted in severely
FT                                impaired phenylalanine-tRNA ligase
FT                                activity). {ECO:0000269|PubMed:26553276}.
FT                                /FTId=VAR_077044.
FT   VARIANT     144    144       Y -> C (in COXPD14; results in decreased
FT                                affinity for tRNA causing a decrease in
FT                                the catalytic efficiency for tRNA
FT                                charging; does not affect ATP or Phe
FT                                binding; dbSNP:rs397514610).
FT                                {ECO:0000269|PubMed:22499341,
FT                                ECO:0000269|PubMed:22833457}.
FT                                /FTId=VAR_069487.
FT   VARIANT     280    280       N -> S (in dbSNP:rs11243011).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_052643.
FT   VARIANT     329    329       I -> T (in COXPD14; results in a 4-fold
FT                                decrease in the catalytic efficiency of
FT                                amino acid activation mainly due to a
FT                                decreased affinity for ATP; does not
FT                                affect Phe binding; affects the stability
FT                                of the enzyme, leading to a significant
FT                                decrease in overall charging capacity;
FT                                dbSNP:rs397514611).
FT                                {ECO:0000269|PubMed:22833457}.
FT                                /FTId=VAR_069488.
FT   VARIANT     391    391       D -> V (in COXPD14; results in a decrease
FT                                in affinity for Phe causing a decrease in
FT                                aminoacylation activity; affects the
FT                                stability of the enzyme, leading to a
FT                                significant decrease in overall charging
FT                                capacity; dbSNP:rs397514612).
FT                                {ECO:0000269|PubMed:22833457}.
FT                                /FTId=VAR_069489.
FT   CONFLICT    158    158       A -> T (in Ref. 4; BAD97143).
FT                                {ECO:0000305}.
FT   CONFLICT    361    361       P -> T (in Ref. 7; AAF28998).
FT                                {ECO:0000305}.
FT   STRAND       49     53       {ECO:0000244|PDB:3CMQ}.
FT   STRAND       56     59       {ECO:0000244|PDB:3CMQ}.
FT   HELIX        68     71       {ECO:0000244|PDB:3CMQ}.
FT   TURN         72     75       {ECO:0000244|PDB:3CMQ}.
FT   HELIX        78     80       {ECO:0000244|PDB:3CMQ}.
FT   STRAND       81     84       {ECO:0000244|PDB:3TUP}.
FT   HELIX        85    103       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      105    107       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      111    113       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      118    121       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       122    125       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       127    129       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       136    138       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       140    142       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      145    152       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       156    159       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       160    165       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      169    178       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      184    186       {ECO:0000244|PDB:3TUP}.
FT   STRAND      189    201       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       202    205       {ECO:0000244|PDB:3CMQ}.
FT   TURN        206    208       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       212    214       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       233    255       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       256    258       {ECO:0000244|PDB:3HFV}.
FT   STRAND      261    268       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      271    281       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      284    294       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       296    301       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      307    315       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       316    323       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       329    333       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       337    340       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       341    343       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      363    370       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       378    389       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       390    392       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      393    403       {ECO:0000244|PDB:3CMQ}.
FT   TURN        405    407       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      410    418       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      421    423       {ECO:0000244|PDB:3CMQ}.
FT   HELIX       427    444       {ECO:0000244|PDB:3CMQ}.
FT   STRAND      448    451       {ECO:0000244|PDB:3HFV}.
SQ   SEQUENCE   451 AA;  52357 MW;  1E5CC647A4A7193B CRC64;
     MVGSALRRGA HAYVYLVSKA SHISRGHQHQ AWGSRPPAAE CATQRAPGSV VELLGKSYPQ
     DDHSNLTRKV LTRVGRNLHN QQHHPLWLIK ERVKEHFYKQ YVGRFGTPLF SVYDNLSPVV
     TTWQNFDSLL IPADHPSRKK GDNYYLNRTH MLRAHTSAHQ WDLLHAGLDA FLVVGDVYRR
     DQIDSQHYPI FHQLEAVRLF SKHELFAGIK DGESLQLFEQ SSRSAHKQET HTMEAVKLVE
     FDLKQTLTRL MAHLFGDELE IRWVDCYFPF THPSFEMEIN FHGEWLEVLG CGVMEQQLVN
     SAGAQDRIGW AFGLGLERLA MILYDIPDIR LFWCEDERFL KQFCVSNINQ KVKFQPLSKY
     PAVINDISFW LPSENYAEND FYDLVRTIGG DLVEKVDLID KFVHPKTHKT SHCYRITYRH
     MERTLSQREV RHIHQALQEA AVQLLGVEGR F
//
